Completed OBSERVATIONAL NCT03898570

Distributed Registry

Distributed Registry Study

Sponsor: AstraZeneca

Conditions Arterial Occlusive Diseases Arteriosclerosis Atherosclerosis Cardiovascular Diseases Intermittent Claudication Patient Compliance Peripheral Arterial Disease Peripheral Vascular Diseases Signs and Symptoms Vascular Diseases

Interventions Patient reported outcomes

Updated 7 times since 2019 Last updated: May 8, 2023 Started: Apr 1, 2019 Primary completion: Sep 30, 2019 Completion: Mar 1, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Arterial Occlusive Diseases and Arteriosclerosis, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 7 data snapshots since 2019. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jun 2023 — Jul 2024 [monthly]

Completed

Status: Unknown Status → Completed
Oct 2021 — Jun 2023 [monthly]

Unknown Status

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting

▶ Show 2 earlier versions

Jun 2019 — Jan 2021 [monthly]

Recruiting

Status: Not Yet Recruiting → Recruiting
May 2019 — Jun 2019 [monthly]

Not Yet Recruiting

First recorded

Apr 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Stanford University

Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Palo Alto, United States